Invest in the Future of Immunotherapy

Our Story

BioVaxys Technology Inc., established in 2018, builds upon the pioneering work in protein haptenization by Dr. David Berd at Thomas Jefferson University and his previous vaccine development at Avax Technologies, Inc. The company focuses on advancing haptenized protein vaccine platforms for viral infections and solid tumors, utilizing a methodology that enhances immune system recognition of target proteins. The acquisition of IMV Inc. added the innovative DPX™ delivery technology to BioVaxys' arsenal, a lipid-based formulation that effectively directs immune responses and has shown promise in various cancer immunotherapies. This strategic expansion has positioned BioVaxys at the forefront of developing effective, well-tolerated treatments for cancer and infectious diseases, marking a significant evolution in its vaccine development journey.
No items found.
Sign up to receive our latest updates in your mailbox
Your data is valuable and we will never sell or share it without your permission. By signing up to receive notifications from us, you agree to our Privacy policy.

Financial Updates